Medicago, GSK tout positive COVID-19 vaccine results

By The Science Advisory Board staff writers

May 19, 2021 -- Medicago and GlaxoSmithKline (GSK) announced positive interim phase II results for their adjuvanted COVID-19 vaccine candidate.

Medicago's plant-based vaccine, coronavirus viruslike particle (CoVLP), which has been tested with GSK's adjuvant, showed a similar antibody response in adults and elderly individuals after they received two doses. Those vaccinated experienced neutralizing antibody responses that were 10 times higher than those who were recovering from the novel coronavirus.

No severe adverse events were reported, according to the companies.

The companies launched the phase III trial of the vaccine candidate in March 2021 and will enroll up to 30,000 individuals worldwide.

Sanofi, GSK COVID-19 vaccine to advance to phase III trials
Sanofi and GlaxoSmithKline's (GSK's) adjuvanted, recombinant COVID-19 vaccine candidate produced strong rates of neutralizing antibody responses in all...
Medicago, GSK start phase III of COVID-19 vaccine trial
Medicago and GlaxoSmithKline (GSK) have started phase III of their adjuvanted COVID-19 vaccine candidate clinical trial.
Medicago, GSK begin phase II/III trial of adjuvanted COVID-19 vaccine
Medicago and GlaxoSmithKline (GSK) have begun a phase II/III clinical trial of their plant-derived COVID-19 vaccine candidate.
If successful, COVID-19 vaccines could be worth $27B
Vaccines are considered one of the most effective public health measures preventing diseases in the modern world. They could also be very profitable endeavors,...
COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter